As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
May 6, 2021


Genopole biotech companies are at the forefront of the Healthtech industry through their innovation. 
Invest4Biotech - Demo Day Genopole 2021 Invest4Biotech - Demo Day Genopole 2021

Following the successful completion of our acceleration program, we are organizing a digital event Invest4biotech, our Demo Day to help our startups to raise their seed and series A.

We are inviting french and international investors to join us online on may 6.

This event will be divided in two sessions:

  1. Pitch session 
    9 startups will pitch on may May 6 between 4pm and 6pm (CET) online followed with a Q/A session at the end of their each pitch.
  2. Partnering session 
    1-to-1 meetings will take place through a partnering platform between on May 6 after from 6pm (CET) and May  7.
    You will be able to book a meeting starting may May 5 up until after the pitch session.

Links to the pitch session and the partnering sessions will be sent to you after registration.

Who is pitching ?

  • #Biotech

    Seekyo is a biotechnology company developing a “smart chemotherapy”: selective to tumors, safe for patients.

    Theranovir is conducting preclinical development of first in class drug candidates in 3 fields :
    1/ in immuno-oncology to address therapy resistance
    2/ in obesity to find an alternative to bariatric surgery
    3/ as repurposing strategy, against infectious diseases.

    Lamark develops extra-stable formulations of biotherapeutics for age-related macular degeneration, antivirals and cancer.

    Fabmid develops a cutting-edge DNA vector to reduce the cost and improve efficiency of cell and gene therapy.

    Cell Environment is currently developing a high throughput cyto-genomic approach towards precise, fast and accessible genetic tests for personalized medicine.

    INNOVHEM is developing solutions that will improve clinical care of patients and promote the development and optimization of treatments for the most common genetic disease, Sickle Cell Disease.

  • #AI-driven Biotech

    WhiteLab Genomics develops Catalyst, an innovative AI platform dedicated to accelerate the design and development of gene and cell therapies.

    AgenT is developing the first blood test to diagnose Alzheimer’s early when it can be prevented.

  • #Bioproduction

    Proteinea is building the next-gen biomanufacturing platform.

With the support from
Région île de France